Breaking Finance News

Wedbush announced Endocyte (NDAQ:ECYT), bumping down its price target to $2.00 earlier today

Indicating a possible upside of 0.14%, Wedbush reduced the stock price target of Endocyte (NDAQ:ECYT) to $2.00

On 5/12/2017, Wedbush released a statement for Endocyte (NDAQ:ECYT) bumped up the target price from $0.00 to $18.00 that suggested an upside of 5.21%.

Boasting a price of $1.75, Endocyte (NDAQ:ECYT) traded 1.05% higher on the day. With the last stock price close down 114.75% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Endocyte has recorded a 50-day average of $2.49 and a two hundred day average of $2.03. Volume of trade was down over the average, with 1,298,233 shares of ECYT changing hands under the typical 2,899,550

Performance Chart

Endocyte (NDAQ:ECYT)

With a total market value of $0, Endocyte has with a one year low of $1.17 and a one year high of $6.55 .

Brief Synopsis About Endocyte (NDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.